- |||||||||| NurOwn (MSC-NTF) / BrainStorm Cell Therap
Enrollment closed, Enrollment change, Trial completion date, Trial primary completion date: Safety and Efficacy of Repeated Administrations of NurOwn® in ALS Patients (clinicaltrials.gov) - Oct 30, 2019 P3, N=261, Active, not recruiting, Recruiting --> Active, not recruiting | N=200 --> 261 | Trial completion date: Jul 2020 --> Dec 2020 | Trial primary completion date: Jul 2019 --> Oct 2020
- |||||||||| NurOwn (MSC-NTF) / BrainStorm
Disability Improvement Assessed by Multiple Sclerosis Functional Composite in Progressive MS Patients from the CLIMB Study (Poster Exhibition) - Aug 28, 2019 - Abstract #ECTRIMS2019ECTRIMS_1580; P2 9HPT and T25FW provide alternative measures of disability improvement in MS patients. A small proportion (~6%) of progressive MS patients experience ≥ 25% improvement in these measures over 12 months, this may serve as a benchmark for new therapeutic strategies and will inform analysis of clinical outcomes in the ongoing phase 2 clinical trial of MSC-NTF cells in progressive MS.
- |||||||||| NurOwn (MSC-NTF) / BrainStorm Cell Therap
Enrollment open: Safety and Efficacy of Repeated Administration of NurOwn (MSC-NTF Cells) in Participants With Progressive MS (clinicaltrials.gov) - Jul 8, 2019 P2, N=20, Recruiting, A small proportion (~6%) of progressive MS patients experience ≥ 25% improvement in these measures over 12 months, this may serve as a benchmark for new therapeutic strategies and will inform analysis of clinical outcomes in the ongoing phase 2 clinical trial of MSC-NTF cells in progressive MS. Not yet recruiting --> Recruiting
- |||||||||| NurOwn (MSC-NTF) / BrainStorm Cell Therap
Trial completion date, Trial primary completion date: Safety and Efficacy of Repeated Administrations of NurOwn® in ALS Patients (clinicaltrials.gov) - Mar 26, 2019 P3, N=200, Recruiting, Not yet recruiting --> Recruiting Trial completion date: Jul 2019 --> Jul 2020 | Trial primary completion date: Apr 2019 --> Jul 2019
|